BioCentury | Apr 13, 2017
Company News

Alteogen, Qilu deal

...Alteogen Inc. (KOSDAQ:196170), Daejeon, South Korea Qilu Pharmaceutical Co. Ltd. , Jinan, China Business: Cancer, Biosimilars Julian Zhu ALT-L2 Alteogen Inc. Qilu...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...the combined value of CrystalGenomics Inc. (KOSDAQ:083790), LegoChem BioSciences Inc. (KOSDAQ:141080), Peptron Inc. (KOSDAQ:087010) and Alteogen Inc....
...PharmAbcine suggested tanibirumab may also have a larger therapeutic window based on Phase I data. Alteogen Inc....
...EVP of business development at LG and prior to that spent 10 years in R&D. Alteogen...
BioCentury | Nov 9, 2015
Company News

Alteogen, 3SBio deal

...of EGFR2 ( HER2 ; ErbB2 ; neu) is based on Alteogen’s NexMab platform technology. Alteogen...
...is eligible for undisclosed milestones and royalties. The companies declined to provide further financial terms. Alteogen Inc....
Items per page:
1 - 3 of 3
BioCentury | Apr 13, 2017
Company News

Alteogen, Qilu deal

...Alteogen Inc. (KOSDAQ:196170), Daejeon, South Korea Qilu Pharmaceutical Co. Ltd. , Jinan, China Business: Cancer, Biosimilars Julian Zhu ALT-L2 Alteogen Inc. Qilu...
BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

...the combined value of CrystalGenomics Inc. (KOSDAQ:083790), LegoChem BioSciences Inc. (KOSDAQ:141080), Peptron Inc. (KOSDAQ:087010) and Alteogen Inc....
...PharmAbcine suggested tanibirumab may also have a larger therapeutic window based on Phase I data. Alteogen Inc....
...EVP of business development at LG and prior to that spent 10 years in R&D. Alteogen...
BioCentury | Nov 9, 2015
Company News

Alteogen, 3SBio deal

...of EGFR2 ( HER2 ; ErbB2 ; neu) is based on Alteogen’s NexMab platform technology. Alteogen...
...is eligible for undisclosed milestones and royalties. The companies declined to provide further financial terms. Alteogen Inc....
Items per page:
1 - 3 of 3